StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

436 Study Matches

Post-contracture release radiation for Dupuytren's disease

The purpose of this study is to critically assess the current treatment that patients are undergoing by reviewing routine data collected and adding one additional outcome questionnaire solely for research purposes

Principal Investigator: Leslie Chang
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00002191
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• diagnoses of Dupuytren's disease
• English-speaking
Exclusion Criteria:

• people who have Dupuytren's disease and are not currently seeking treatment
Keywords: Dupuytren Contracture, Dupuytren's Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

MTT for H.S. Investigate whether restoring normal gut microbiome composition with cMTT influences the relative overabundance of anaerobic bacteria and microbial diversity of the skin in patients with HS

This research is being done to gain a better understanding of Hidradenitis Suppurativa (HS) and treatment with oral capsule microbiota transplant therapy (MTT) and the effects. Participants will be randomized (by chance) into 1 of 2 groups, treatment or placebo (no active ingredients) group. This study will last for up to 6 months

Principal Investigator: Noah Goldfarb
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00018878
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• diagnosis of Hidradenitis Suppurativa (HS)
• able to speak English
• women who are of child bearing age must use a highly effective form of birth control
• must be on a stable dose of medications for at least 30 days before starting the study
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• planning on moving within 6 months from start of study
• history of anaphylactic food allergies
• women who are pregnant, breastfeeding or planning to get pregnant during the time of the study
• history of inflammatory bowel disease or extensive bowel surgery
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Dermatology (Skin, Hair & Nails)
Keywords: Hidradenitis Suppurativa, HS
I'm interested
Share via email
See this study on ClinicalTrials.gov

Magnetic Resonance Imaging of Osteonecrosis of the Femoral Head

The purpose of this research study is to investigate new magnetic resonance imaging (MRI) methods to better detect and monitor osteonecrosis of the femoral head (ONFH) before and after treatment. ONFH causes injury to the hip joint that can lead to osteoarthritis (the breaking/wearing down of cartilage & tissues within the joint) and the eventual need for a hip replacement. It can be difficult to detect ONFH early on using current medical imaging techniques, which is when treatments may be the most effective. Furthermore, available treatments are not always effective at preventing the progression (spread or growth) of ONFH. This research may benefit others with ONFH by providing more effective medical imaging tools to detect ONFH earlier and inform treatment decisions to increase the chance of stopping or delaying the progression of ONFH and preventing hip osteoarthritis.

Principal Investigator: Casey Johnson
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00016964
Show full eligibility criteria
Hide eligibility criteria
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosed with Stage 1 or Stage 2 osteonecrosis of the femoral head (ONFH)
• intend to have core decompression surgery to treat the ONFH
Exclusion Criteria:

• excluded from having an MRI based on Center for Magnetic Resonance Research (CMRR) safety criteria
• existing implantation of metal device in affected hip
• any health conditions that would pose a challenge for you to participate
• unavailable to undergo follow up MRI 6 months after core decompression treatment
Conditions: Bone, Joint & Muscle
Keywords: aging, core decompression treatment, MRI, Osteonecrosis, early diagnosis, hip
I'm interested
Share via email

Vibrotactile stimulation of the larynx to treat unexplained chronic cough

This is a study of adults with unexplained chronic cough between 18-88 years old. This study is trying to determine whether a noninvasive vibrotactile stimulation device can help reduce cough symptoms.

Principal Investigator: Stephanie Misono
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00012174
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• adults aged 18-88
• more than 8 weeks of non-productive cough
• chest x-ray or chest CT negative (collected as part of routine clinical care); no time limit on imaging (if available)
• clinical impression that untreated or inadequately treated gastroesophageal, pulmonary, and/or sinus or nasal issue is not the reason for the cough
• able to read and speak English
Exclusion Criteria:

• current smoker or quit less than 3 months ago
• infectious cause for cough (e.g., TB, pertussis, COVID)
• history of known or suspected aspiration pneumonia
• Diagnosis or clinical suspicion of chronic obstructive pulmonary disease (COPD)
• Diagnosis or clinical suspicion of interstitial lung disease (ILD)
• Unmanaged reflux
• Unmanaged allergies/postnasal drip
• recent intubation/neck surgery (within 8 weeks)
• neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA)
• untreated carotid artery disease
• electronic implants (e.g., pacemaker)
• specific medications (study staff will discuss)
• anticipate use of new medications to treat the cough during the period of the study
• currently having speech therapy for cough
• BMI > 40 (for transmission of VTS through soft tissue)
• allergy to adhesives
• Current or recent drug/alcohol dependency or abuse (stopped or completed treatment less than 6 months)
• pregnant
• without regular access to wifi and internet
Conditions: Breathing, Lung & Sleep Health, Ear, Nose & Throat
Keywords: chronic cough, cough, larynx, vibrotactile stimulation, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

BEETroot juice to reverse functional impairment in PAD: The BEET PAD Trial (BEET PAD)

The BEET PAD Trial is a multi-centered double-blind randomized clinical trial of beetroot juice vs. placebo in 210 people with PAD. We hypothesize that by simultaneously increasing lower extremity perfusion, gastrocnemius muscle mitochondrial activity, and myofiber health and regeneration, beetroot juice will significantly improve walking performance in people with PAD. Our primary aim is to determine whether beetroot juice significantly improves six-minute walk distance at 4-month follow-up in people with PAD, compared to placebo. Preliminary evidence suggests that beetroot juice has both acute and chronic effects on walking performance in PAD. Our primary outcome will measure the combined acute and chronic effect of beetroot juice (i.e. the maximal effect) on change in 6-minute walk at 4-month follow-up. In secondary aims, we will distinguish between acute and chronic effects of beetroot juice on six-minute walk and delineate biologic pathways by which beetroot juice improves walking performance in PAD, by measuring change in gastrocnemius muscle perfusion (MRI arterial spin labeling), and gastrocnemius muscle health. We will assess the durability of beetroot juice effects on six-minute walk. Nitrate in beetroot juice is metabolized to nitrite and subsequently to NO, attaining peak nitrite levels 2.5 hours after ingestion (1). Inter-individual variability exists in the extent of metabolic conversion of nitrate to nitrite (1,2). Therefore, we will determine whether a higher peak or a greater increase in plasma nitrite at 2.5 hours after beetroot juice consumption at baseline has a greater effect on six-minute walk at 4-month follow-up, compared to a lower peak or a smaller increase, respectively. To achieve our specific aims, we will randomize 210 participants age 50 and older with PAD to one of two groups: beetroot juice vs placebo. Participants will be followed for 4.5 months.

Principal Investigator: Diane Treat-Jacobson
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022643
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Diagnosis of peripheral artery disease (PAD)
• 50 years of age or older
Exclusion Criteria:

• Above- or below-knee amputation
• Critical limb ischemia symptoms of rest pain
• Wheelchair or walker is needed to walk
• Walking is limited by a symptom other than PAD
• Current foot ulcer on bottom of foot
• Planned major surgery, coronary or leg revascularization during the next five months
• Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
• Major medical illness including lung disease requiring oxygen, Parkinson’s disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years
• Allergy to beetroot juice
• Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study
• Currently eating one cup or more of beets daily
• Non-English speaking
• Participation in or completion of a clinical trial in the previous three months
• Visual impairment that limits walking ability
• Participation in a supervised treadmill exercise program in previous three months or planning to begin a supervised treadmill exercise program in the next five months
Conditions: Heart & Vascular
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa Topical Ruxolitinib Evaluation in Hidradenitis Suppurativa (TRuE-HS1)

Hidradenitis Suppurativa (HS) is a chronic condition that causes bumps or boils, often in the folds of armpits, chest, breasts, groin, stomach, back or sides, or buttocks. This Study is being done to compare the safety and effectiveness of a Study Drug called ruxolitinib cream with a vehicle cream for people with hidradenitis suppurative. A vehicle cream looks like the Study Cream but does not have active drug in it. Participants will be in the Study for approximately 60 weeks. This includes a 28-day screening period, 16 weeks of receiving either the Study Cream or vehicle cream, 36 weeks of receiving the Study Cream, and a 30-day follow-up.

Principal Investigator: Noah Goldfarb
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00025137
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of Hidradenitis Suppurativa (HS) at least 6 months before starting the study
• see link to clincialtrials.gov for complete inclusion criteria
Exclusion Criteria:

• people who have cancer
• women who are pregnant or breastfeeding
• see link to clincialtrials.gov for complete exclusion criteria
Conditions: Dermatology (Skin, Hair & Nails)
Keywords: Hidradenitis Suppurativa, HS1
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2024-07:A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus (RESET-SLE)

The purpose of this study is to find out what dose of CABA-201 can be safely administered to patients with SLE, including those with lupus nephritis (LN). SLE is thought to involve B cells that cause the body to attack different tissues in the body including your skin, joints, kidneys, heart, lungs, brain, and blood cells. LN is a type of kidney disease caused by SLE. CABA-201 is a chimeric antigen receptor T cell (CAR T) therapy. In this study, we will take some of your T cells, a type of white blood cell, and genetically modify them (put in a “code”) so that they may find and remove the B cells in your body, including the B cells that are involved in causing your disease. Once your cells are modified, CABA-201 cells will be re-infused into your body intravenously (through the vein).

Principal Investigator: Patrick Nachman
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019751
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 65 years old
• diagnosis of Systemic Lupus Erythematosus (SLE)
• positive antinuclear antibody (ANA) titer or anti-dsDNA antibody
Exclusion Criteria:

• active infection requiring medical intervention
• presence of kidney disease other than active lupus nephritis
• prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.
• additional medical conditions (study staff will review)
Conditions: Immune Diseases
Keywords: Clinics and Surgery Center (CSC), Lupus, Lupus Nephritis, SLE, Systemic Lupus Erythematosus
I'm interested
Share via email
See this study on ClinicalTrials.gov

Evaluation of an oral microbiota-based therapeutic as a treatment option for primary sclerosing cholangitis

We are studying the safety and feasibility of microbiota transplant therapy (MTT) for patients with Primary Sclerosing Cholangitis (PSC). The purpose of this study is to evaluate whether MTT from a healthy donor is safe and can be used to restore the healthy composition of microbiota to help decrease disease severity and improve symptoms. All patients in this study will receive capsules of the drug, MTT.

Principal Investigator: Elizabeth Aby
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020840
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• ages 18-76
• serum total bilirubin ≤ 2x the upper limit of normal
• expect to maintain current medication regimen for the duration of the study
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• received antibiotic therapy (except vancomycin) in the past 3 months
• complications of advanced PSC, such as hepatic encephalopathy, ascites, history of esophageal varices, portal hypertension, hepato-renal syndrome, portopulmonary syndrome, and hepato-pulmonary syndrome
• viral hepatitis (history of Hepatitis C is eligible with undetectable HCV RNA); HIV/AIDS
• liver disease such as metabolic or inherited disease or cirrhosis
• women who are pregnant, breast feeding, or trying to become pregnant -active cancer
• active alcohol overuse (>4 drinks per day for men, and >2 drinks per day for women)
Conditions: Digestive & Liver Health, Microbiota
Keywords: Clinics and Surgery Center (CSC), Primary Sclerosing Cholangitis, PSC
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months

The purpose of this study is to learn the effects, good or bad, of the study drug, vosoritide, for treating children who have hypochondroplasia. This condition affects the growth of bone and cartilage and in which kids who have it are shorter than other kids of the same age. In this study, your child will get either the study drug or placebo, which is an inactive medicine.

Principal Investigator: Brad Miller, MD, PhD
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00026654
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 0 months to less than 36 months old
• confirmed genetic diagnosis of Hypochondroplasia (HCH)
• participant's weight must be ≥ 3 kg (6.6 pounds)
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• short stature condition other than HCH
• have an unstable medical condition
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Diabetes & Endocrine, Rare Diseases
Keywords: HCH, Hypochondroplasia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Phase I Clinical Trial of iPSC-Based Therapy (MyoPAXon) for Duchenne Muscular Dystrophy

This study aims to find out whether MyoPAXon, a genetically modified cellular therapy treatment, is safe to give to patients with Duchenne Muscular Dystrophy (DMD), and whether it has any positive effect on their disease. It will also determine how much MyoPAXon is safe to give to a person at one time.

Principal Investigator: Peter Kang
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023008
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosed with Duchenne muscular dystrophy (DMD) and non-ambulatory
• age 18 or older
• off investigational treatments for at least 30 days
Exclusion Criteria:

• presence of HLA antibodies directed toward HLA antigens on MyoPAXon
• active treatment with another investigational therapy
• known allergy to MyoPAXon components
Conditions: Bone, Joint & Muscle
Keywords: Clinics and Surgery Center (CSC), DMD, Duchenne Muscular Dystrophy, Muscular Dystrophy
I'm interested
Share via email
See this study on ClinicalTrials.gov

Assessment of Breast and Nipple Sensation Following Nerve Grafting in DIEP Flap Breast Reconstruction: A Prospective Study Using Two-Point Discrimination and Semmes-Weinstein Monofilaments

This study is about quality of life and physical sensation in the nipple-areola area of people who have undergone deep inferior epigastric perforator (DIEP) flap breast reconstruction with or without nerve grafting. At the post-operative clinic visits at 3, 6, 12, and 18-months post-op, participants will have sensory assessments and be asked to complete a series of questionnaires.

Principal Investigator: Umar Choudry
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00025141
Show full eligibility criteria
Hide eligibility criteria
Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18-90 years of age
• assigned gender of female at birth
• having a DIEP flap breast reconstruction with nerve grafting of one or both breasts
Exclusion Criteria:

• peripheral neuropathy or sensory deficits
• having an alternative reconstruction technique or a revision
Conditions: Cancer
Keywords: Breast cancer, DIEP breast reconstruction, reconstructive breast surgery
I'm interested
Share via email

AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

Principal Investigator: Robin Williams
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: SITE00001674
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 50 years of age or younger
• have 4 or less nodules in the lung due to metastases or suspected metastases
• diagnosis of osteosarcoma
• contact study team for more detailed criteria
Exclusion Criteria:

• pleural or mediastinal based metastatic lesions, or with pleural effusion
• large, or central tumors that require a lobectomy or pneumonectomy
Conditions: Cancer
Keywords: lung cancer, osteosarcoma, pulmonary metastases, thoracotomy
I'm interested
Share via email
See this study on ClinicalTrials.gov

ANBL2131/MT2024-35- A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

This phase III trial tests how well adding dinutuximab to induction chemotherapy along with standard of care surgery radiation and stem cell transplantation works for treating children with newly diagnosed high risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. Chemotherapy drugs such as cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, dexrazoxane, doxorubicin, temozolomide, irinotecan and isotretinoin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. During induction, chemotherapy and surgery are used to kill and remove as much tumor as possible. During consolidation, very high doses of chemotherapy are given to kill any remaining cancer cells. This chemotherapy also destroys healthy bone marrow, where blood cells are made. A stem cell transplant is a procedure that helps the body make new healthy blood cells to replace the blood cells that may have been harmed by the cancer and/or chemotherapy. Radiation therapy is also given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of induction.

Principal Investigator: Robin Williams
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022164
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age: less than or equal to 30 years at the time of initial diagnosis with high-risk disease Diagnosis
• Must have a diagnosis of NBL or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
• Newly diagnosed, HRNBL defined as one of the following: a. Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification b. Age:: greater than or equal to 547 days and INRG Stage M regardless of biologic features c. Any; age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to Stage M without systemic chemotherapy d. Age: greater than or equal to 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to Stage M without systemic chemotherapy BSA: Patients must have a BSA greater than or equal to 0.25 m2
Exclusion Criteria:

• Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features.
• Patients ≥547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features.
• Patients with known bone marrow failure syndromes.
• Patients on chronic immunosuppressive medications
• Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy.
• Female patients who are pregnant or breastfeeding their infant.
Conditions: Cancer
Keywords: neuroblastoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Left Sided Stellate Ganglion Blocks Impact on the rate of Post-operative Atrial Fibrillation in patients undergoing Thoracic Surgery: A pilot study

To determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.

Principal Investigator: Jacob Hutchins
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021470
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• patients undergoing esophagectomy, pneumonectomy, or lobectomy
• aged 18-85
Exclusion Criteria:

• patients who have can't have regional anesthesia or stellate blockage
• women who are pregnant
Conditions: Breathing, Lung & Sleep Health
Keywords: esophagectomy, or lobectomy, pneumonectomy, stellate ganglion block
I'm interested
Share via email
See this study on ClinicalTrials.gov

The effects of cigarette smoking and alcohol on DNA damage in the oral cavity

The purpose of this study to examine the effects of cigarette smoking and drinking alcohol on the formation of DNA damage in the mouth. The overall goal is to identify DNA damage that may be important to the development of head and neck cancers.

Principal Investigator: Stephen Hecht, PhD
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00021212
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• Healthy individuals
• over 30 years old
• have 7 or more alcoholic drinks per week
Exclusion Criteria:

• Use tobacco/nicotine products
• Unstable health
Conditions: Prevention & Wellness, Cancer
Keywords: Alcohol, beer, liquor, ADH, drinking
I'm interested
Share via email

MT2023-29: Long-term Follow-up of Subjects With Sickle Cell Disease Treated With ExVivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

The purpose of this study is to evaluate the long-term safety and ability of a transplant with gene modified stem cells (autologous stem cell transplant) to treat sickle cell disease. Participants must have received investigational gene therapy with bb1111 in a clinical study sponsored by bluebird bio. There is no additional treatment associated with this study as this is a long-term follow-up study.

Principal Investigator: Ashish Gupta
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020842
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 2 to 53 years old
• treated with a clinical product to Sickle Cell Disease (SCD) in clinical study sponsored by bluebird bio-
Exclusion Criteria:

• there are no exclusion criteria for this study
Conditions: Rare Diseases, Blood Disorders
Keywords: SCD, Sickle Cell, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

We are comparing treatment of early stage, hormone positive breast cancer with and without radiation therapy. One group will receive radiation therapy with endocrine therapy and the other group will receive endocrine therapy alone. We want to find out if there is any difference in how often breast cancer recurs in the same breast.

Principal Investigator: Jocelin Huang
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC044
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• completed surgery to remove a breast tumor and there isn't any evidence of remaining tumor.
• Early stage (T1) tumor without lymph node involvement and a Oncotype DX Recurrence Score of less than or equal to 18
• ER and/or PgR positive and HER2 negative tumor
Exclusion Criteria:

• tumor size larger that T1
• surgical procedure was a mastectomy
• any treatment with radiation therapy, chemotherapy, biotherapy, and/or endocrine therapy given for the currently diagnosed breast cancer prior to study entry
• Women who are pregnant or breast feeding
Conditions: Cancer
Keywords: Breast Cancer, Breast Cancer, Radiation, Stage 1 breast cancer. Hormone positive breast cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

ALTE22C1, Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)

To determine the prevalence, type, and severity of chronic health conditions (CHC) in survivors of Down syndrome-associated acute leukemia (DS-AL), and to compare CHC with frequency-matched DS individuals that have no cancer history.

Principal Investigator: Karim Sadak
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00024697
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age: Patients age >= 6 and < 40 years at the time of enrollment.
• A diagnosis of Down Syndrome is required; all patients must be DS-AL survivors and have been treated for ALL or AML.
• All cancer treatment must have been completed at least 36 calendar months prior to enrollment.
Exclusion Criteria:

• Patients with history of Hematopoietic Stem Cell Transplant (HSCT) are excluded.
• Patients with a history of cancer prior to their ALL or AML diagnosis are excluded. Patients that developed a subsequent malignant neoplasm following their ALL or AML diagnosis are also excluded.
• Patients whose parents or guardians are unable to complete the required forms are excluded.
Conditions: Blood Disorders, Cancer
Keywords: ALL, AML, Clinics and Surgery Center (CSC), Down Syndrome, DS-AL survivors, leukemia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

To determine the prognostic factors for visual outcome for newly diagnosed NF1-OPGs. Hypothesis: Patients (<18 years of age) with tumors involving the optic tracts and/or radiations will demonstrate worse visual outcomes compared to those without optic tract involvement.

Principal Investigator: Clay Hoerig
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: 1606M89501
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 18 years old
• EITHER the clinical diagnosis of NF1 OR have a constitutional NF1 mutation
• newly diagnosed Optic Pathway Glioma (OPG) (confirmed by MRI within 1 month of enrollment)
• additional inclusion and exclusion criteria (study staff will review)
Exclusion Criteria:

• OPGs involving only the optic radiations
• prior therapy for an OPG (e.g. surgery [including biopsy], radiotherapy, chemotherapy, etc.)
• prior therapy for another (non-OPG) tumor
• history of hydrocephalus requiring surgical intervention
Conditions: Cancer, Cancer
Keywords: OPG, Optic Pathway Glioma
I'm interested
Share via email

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]

The purpose of the study is to assess if the study treatment, pelacarsen, taken by people with mild or moderate CAVS and elevated lipoprotein(a) can safely help slow the progression of calcific aortic valve stenosis (CAVS). Pelacarsen is a treatment being tested that acts on a particle called Lp(a), which if elevated, may play a role in CAVS.

Principal Investigator: Daniel Duprez
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022219
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• men and women between the ages of 50 and 79
• diagnosis of mild or moderate calcific aortic valve stenosis
Exclusion Criteria:

• ejection fraction (EF) less than 55%
• severe aortic or mitral valve stenosis
• uncontrolled hypertension
• history of cancer
• women who are pregnant or breast feeding
• unable to have an echocardiogram or CT scan
Conditions: Heart & Vascular
Keywords: Clinics and Surgery Center (CSC), elevated LPa, Aortic Stenosis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Transcatheter Mitral Valve Replacement with the Medtronic Intrepid&#8482; TMVR System in patients with severe symptomatic mitral regurgitation &#8211; APOLLO Trial (APOLLO)

The purpose of this study is to determine if replacing the mitral valve without open-heart surgery is as safe and effective as standard mitral valve surgery in patients with similar medical conditions. This system allows a bioprosthetic mitral valve (investigational valve) to be implanted through a long, thin, flexible tube that is inserted through an incision in the side of the chest or through an incision made in the groin area and through a vein in the leg. Participation in the study is expected to last approximately 5 years from the day the valve is implanted.

Principal Investigator: Greg Helmer
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00017497
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of moderate or severe mitral value regurgitation with symptoms
• multidisciplinary heart team thinks patient is not able to have treatment an approved transcatheter repair or conventional mitral valve procedure
Exclusion Criteria:

• prior transcatheter mitral valve procedure with device currently implanted
• left ventricular ejection fraction <30%
Conditions: Heart & Vascular
Keywords: Clinics and Surgery Center (CSC), Intrepid, Mitral valve, Mitral Valve Replacement, TAVR

A Prospective, Multi-Center, Open Label, Randomized Control Clinical Trial Evaluating the Safety and Efficacy of the Cordella&#8482; Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class II Heart Failure Patients (PROACTIVE- HF-2 Trial)

The Cordella™ Pulmonary Artery Sensor System is a possible treatment for New York Heart Association (NYHA) Class II and III heart failure. The main purpose of this study is to investigate the safety and effectiveness of the study device in helping to reduce Heart Failure hospitalizations.

Principal Investigator: Tamas Alexy
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00021914
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Heart Failure NYHA Class II or Class III
Exclusion Criteria:

• ACC/AHA Stage D refractory Heart Failure (HF)
• history of multiple pulmonary embolism (PE)
• resting systolic blood pressure less than 90 mmHg
Conditions: Heart & Vascular
Keywords: Cardiovascular, Clinics and Surgery Center (CSC), Heart Failure, HF
I'm interested
Share via email
See this study on ClinicalTrials.gov

Neurodevelopmental Outcomes for CMV Infections Identified by Newborn Screening

This research study is about early development in children diagnosed with congenital cytomegalovirus infection (cCMV), identified by newborn screening that has been confirmed with a follow-up test. Study visits, when the child is 12, 24 and 36 months of age, will include questionnaires, direct assessment of child and interviews with parent(s). A brain MRI will also be completed at about 12 months. Parents will receive a report summarizing a child’s developmental, language, and behavioral assessments, reported as within normal ranges or if clinical follow-up is recommended.

Principal Investigator: Meghan Swanson
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00026268
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 14 months old
• tested positive for congenital cytomegalovirus (also called cCMV or CMV) on the newborn heel / blood spot screening test
• parent/guardian is able to complete study visits, interviews and questionnaires in English
Exclusion Criteria:

• certain medical conditions that study staff will screen for during the process of joining the study
Conditions: Brain & Nervous System, Children's Health, Infectious Diseases
Keywords: Cytomegalovirus, CMV, Sensorineural hearing loss, Infant, Baby, Schleiss
Visit study website
I'm interested
Share via email

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy (BLOSSOM)

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect various organs of the body, especially the skin, joints, blood, kidneys and central nervous system. "Chronic" means that it can last for a long time. "Autoimmune" means that there is a disorder of the immune system, which, instead of protecting the body from bacteria and viruses, attacks the one’s own tissues. We are doing this study to see if the investigational medication called anifrolumab may have an effect in treating pediatric SLE, to see how well it is tolerated or how safe it is, to measure levels of anifrolumab in the blood and learn more about the disease and associated health problems.

Principal Investigator: Bryce Binstadt
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020549
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 5 years to less than 18 years old
• weight at lest 15 kg (33 pounds)
• diagnosis of Systemic Lupus Erythematosus (SLE)
• being treated with prednisone, or antimalarial drugs
• no active or chronic TB or contact with someone who has TB
• females and males must be willing to use birth control during the study
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
Exclusion Criteria:

• history of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months
• history of multiple infections requiring hospitalization and IV antibiotics over the past year
• history of cancer
• history of severe COVID-19 infection
• prior treatment with anifrolumab
Conditions: Arthritis & Rheumatic Diseases, Immune Diseases, Rare Diseases
Keywords: Diagnosis of SLE, Lupus, Systemic Lupus Erythematosus
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer

The goal of this current study is to test whether men with prostate cancer that is getting worse after treatment with hormone therapy and abiraterone respond better to alternating treatment with testosterone and enzalutamide vs. enzalutamide alone. We are testing to see which is better at stopping tumor growth that can be seen on a bone scan or CT scan and the effect of each regimen on lowering Prostate Specific Antigen (PSA values). Participants will be in the study for 6 to 24 months.

Principal Investigator: Emmanuel Antonarakis
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001730
Show full eligibility criteria
Hide eligibility criteria
Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of adenocarcinoma of the prostate
• spread (metastatic) to other organs or bone
• one chemotherapy treatment for hormone sensitive prostate cancer is allowed
• previous treatment required, study staff will review
• able to care for self with little help
Exclusion Criteria:

• prior chemotherapy with docetaxel or cabazitaxel for CRPC
• other severe medical conditions, study staff will review
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Castration Resistant Metastatic Prostate Cancer (CRPC), Prostate cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

AALL2321; A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

To evaluate the addition of two cycles of blinatumomab for all infants with newly diagnosed ALL and will evaluate in a randomized manner the safety, tolerability, and early activity of venetoclax in infants with KMT2A-R ALL.

Principal Investigator: Peter Gordon
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00025534
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Eligibility Screening: All patients must be enrolled on APEC14B1 and consented to Eligibility Screening (Part A) prior to treatment and enrollment on AALL2321.
• Age: Infants (aged 365 days or less) on the date of diagnosis are eligible; infants must be > 36 weeks gestational age at the time of enrollment.
• Diagnosis: Patients must have newly diagnosed B-acute lymphoblastic leukemia (B-ALL, 2017 WHO classification), also termed B-precursor ALL, or acute leukemia of ambiguous lineage (ALAL), which includes mixed phenotype acute leukemia. For patients with ALAL, the immunophenotype of the leukemia must comprise at least 50% B lineage.
Exclusion Criteria:

• Patients with Down Syndrome.
• Patients with secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy.
• Prior therapy: Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of infant ALL or for any cancer diagnosis prior to the initiation of protocol therapy.
Conditions: Blood Disorders, Cancer, Children's Health
Keywords: ALL, KMT2A-G, KMT2A-R, KMT2A-Rearranged, Newly Diagnosed Acute Lymphoblastic Leukemia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Individualized Diabetes Education Assisted by CGM (IDEA-CGM)

This study aims to learn more about how continuous glucose monitor (CGM) data can be used to personalize lifestyle interventions for type 2 diabetes. Participation in the study would require 4-5 clinic visits over a period of 14 weeks. Participants will also be asked to: meet with study staff every 2 weeks (virtually), keep food logs, periodically wear an activity monitor and/or a CGM, answer survey questions, and provide blood samples to measure markers of diabetes control (like hemoglobin A1c).

Principal Investigator: Anne Bantle
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022947
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• At least 18 years of age
• Diagnosis of type 2 diabetes mellitus
• Hemoglobin A1c of 6.8 – 8.5 %
• Stable medications for diabetes for at least 3 months prior to enrollment, with no plans to change medications or doses during the intervention period
Exclusion Criteria:

• Type 1 diabetes mellitus
• Treatment with insulin, sulfonylurea, or meglitinide
• Use of a non-diabetes medication affecting blood glucose (e.g. corticosteroid)
• BMI < 25 kg/m2, or <23 kg/m2 for participants who self-identify as Asian
• Weight change > 5 pounds in the 3 months prior to study enrollment
• Estimated glomerular filtration rate <60 ml/minute/1.73 m2
• Pregnant or breastfeeding
• Anemia
• Changes to diabetes medications, including change in dose, in the 3 months prior to enrollment
• Presence of any disease that would make adherence to the protocol difficult
Conditions: Diabetes & Endocrine
Keywords: blood glucose, blood sugar, continuous glucose monitor (CGM), Diet, nutrition
I'm interested
Share via email
See this study on ClinicalTrials.gov

PROmote weight loss in obese PAD patients to preVEnt mobility Loss: The PROVE Trial (PROVE)

More than 65% of people with lower extremity peripheral artery disease (PAD) are overweight or obese. Overweight or obese people with PAD have greater functional impairment and faster functional decline than normal weight people with PAD. Walking exercise is first line therapy to improve walking performance in PAD. However, our NHLBI-funded observational longitudinal study of functional decline in PAD showed that overweight and obese PAD participants who combined weight loss with walking exercise had significantly less functional decline than those who walked for exercise but did not lose weight. Therefore, we hypothesize that among people with PAD who are overweight or obese, a weight loss intervention combined with exercise will improve walking ability more than exercise alone. However, the effects of intentional weight loss in overweight or obese people with PAD are unknown and may not be beneficial if weight loss exacerbates PAD-related sarcopenia. Behavior change that achieves sustained weight loss is particularly challenging in older obese people with chronic disease. Therefore, among people with PAD and BMI>28 kg/m2, we will conduct a randomized clinical trial to test the hypothesis that a weight loss intervention combined with walking exercise achieves greater improvement in functional performance than exercise alone at 12-month follow-up.

Principal Investigator: Diane Treat-Jacobson
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00000513
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• diagnosis of Peripheral Artery Disease (PAD) with leg symptoms
• BMI 25kg/m2 or more
Exclusion Criteria:

• above or below knee amputation, critical limb ischemia, or wheelchair confinement
• walking is limited by a condition other than PAD
• heart attack or stroke in the past 3 months
• medical or mental health disease that will interfere with study participations (study staff will review)
• currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention
• unwilling/unable to use a smart phone and unwilling to attend weekly study sessions
• unable to speak English
Conditions: Heart & Vascular
Keywords: aging, cocoa, intercede, pad, peripheral arterial disease, peripheral artery disease, prove
I'm interested
Share via email
See this study on ClinicalTrials.gov

REFORM-HF. REducing Fluid Overload using Renal Independent systeM in Heart Failure Patients (REFORM-HF)

This research study is designed to evaluate a new treatment approach for patients with chronic heart failure. This study will assess the effectiveness and safety of a new medical device, the AquaPass system, in managing the accumulation of fluids in the body that persists despite standard medical treatment. The purpose of this study is to understand if the use of the AquaPass System with medication treatment results in increased fluid removal compared to only regular medication treatment.

Principal Investigator: Tamas Alexy
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022887
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of heart failure NYHA Class II, III who is congested and not responding to usual treatment such as 80mg of lasix (or another diuretic) per day
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• acute worsening of heart failure needing care in the ICU
• arrhythmia, infection, or other medical condition that is causing acute illness
• lower body skin problems (open wounds, ulcers, infections)
• severe peripheral artery disease
• women who are pregnant, breast feeding, or planning to get pregnant during the study period
Conditions: Heart & Vascular
Keywords: Heart Failure, CHF
I'm interested
Share via email
See this study on ClinicalTrials.gov

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary symptoms of Long COVID (REVERSE-LC) (REVERSE-LC)

The purpose of this study is to understand if a drug called baricitinib can help with thinking and memory problems after COVID-19 infection for people suffering with Long COVID. Some people have thinking and memory problems along with possible difficulty breathing, a racing heart, dizziness, and/or fatigue after COVID-19 called Long COVID. This includes things like having a hard time remembering people’s names, managing money, or keeping a job. For some patients, these issues may last several years. We still do not understand why these problems happen and why they last longer in some people. This study will look at the changes in brain function, heart function, and daily activities after taking baricitinib or placebo for people who experience Long COVID.

Principal Investigator: Carolyn Bramante
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022496
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• documented COVID infection 6 or more months prior
• clinical evidence of Long COVID such as fatigue, chills, post-exertional malaise, trouble with memory/concentration ("brain fog"), headache, dysautonomia/postural orthostatic tachycardia syndrome, dizziness, unsteadiness, neuropathy, sleep disturbance, chest pain, palpitations, shortness of breath, cough, fainting spells, muscle aches, joint pain, nausea, diarrhea
• symptoms must have started after January 2020 and be present for at least 6 months prior starting the study
• symptoms must be reported to have an impact on quality of life and/or everyday functioning and to be at least somewhat bothersome
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• severe cognitive, physical, or psychological disability preventing participation
• currently pregnant or breastfeeding or planning to become pregnant or breastfeed during the course of the study
• admission to an ICU for treatment of acute COVID-19 infection
• cancer diagnosis in the past 5 years
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Community Health, Infectious Diseases
Keywords: Coronavirus Infections, COVID-19, Long Covid